AOP Coaches

The AOP development Coaching program (Tanabe et al. 2025) was initiated in 2019. It pairs experienced AOP developers with new contributors to enhance the quality of information populated into the AOP-Wiki, to ensure compliance with guidance in the AOP Developer’s Handbook, and to provide an on-going resource to address contributor questions. The coaching program is an all-volunteer activity.

The roster of previous and current coaches is provided below. To request a coach, please e-mail aopwiki@googlegroups.com OR submit your request on the Request for Coach page on the AOP forum (AOP Guidance and FAQS > AOP Guidance > Request for Coach).

Coach's Name	Affiliation	AOPs assigned for Coaching AOP ID: Title, OECD Status	# of AOPs Coached
Shihori Tanabe	National Institute of Health Sciences	toggle AOPs 271: Inhibition of thyroid peroxidase leading to impaired fertility in fish, Under Development 315: Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response, Under Development 293: Increased DNA damage leading to increased risk of breast cancer, Under Development 294: Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer, Under Development 206: Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis, Under Development 305: 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring, Under Review 306: Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring, Under Review 307: Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring, Under Review 358: Chitinase inhibition leading to mortality, Under Development 359: Chitobiase inhibition leading to mortality, Under Development 360: Chitin synthase 1 inhibition leading to mortality, WPHA/WNT Endorsed 361: Sulfonylureareceptor binding leading to mortality, Under Development 433: hERG channel blockade leading to sudden cardiac death 479: Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress, Under Development 480: Mitochondrial complexes inhibition leading to heart failure via decreased ATP production, Under Development 443: DNA damage and mutations leading to Metastatic Breast Cancer, Under Development 155: Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation, WPHA/WNT Endorsed 156: Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation, WPHA/WNT Endorsed 157: Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation , WPHA/WNT Endorsed 158: Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation, WPHA/WNT Endorsed 159: Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation, WPHA/WNT Endorsed 524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals , Under Review 237: Substance interaction with lung resident cell membrane components leading to atherosclerosis, Under Development 478: Deposition of energy leading to occurrence of cataracts, WPHA/WNT Endorsed 482: Deposition of energy leading to occurrence of bone loss, WPHA/WNT Endorsed 483: Deposition of Energy Leading to Learning and Memory Impairment, WPHA/WNT Endorsed 324: Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation and cell death 325: Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation and reduced cell growth 326: Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation and reduced cell proliferation 331: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death 332: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell growth 333: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation 596: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell injury/death 597: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and reduced cell growth 598: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and reduced cell proliferation 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 600: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell growth 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 603: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell cycle disruption 624: Altered glucocorticoid receptor signaling leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction, Under Development 625: Altered glucocorticoid receptor signaling leading to MASLD progression via reduced very low-density lipoprotein export-associated mitochondrial dysfunction, Under Development 626: Altered glucocorticoid receptor signaling leading to MASLD progression via reduced VLDL export-associated mitochondrial dysfunction, Under Development 627: Altered glucocorticoid receptor signaling leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress, Under Development 628: Altered glucocorticoid receptor signaling leading to MASLD progression via reduced very low-density lipoprotein export-associated endoplasmic reticulum stress, Under Development 629: Altered glucocorticoid receptor signaling leading to MASLD progression via reduced lipogenesis-associated endoplasmic reticulum stress, Under Development	46
Dan Villeneuve	US EPA, Great Lakes Toxicology and Ecology Division	toggle AOPs 271: Inhibition of thyroid peroxidase leading to impaired fertility in fish, Under Development 297: Inhibition of retinaldehyde dehydrogenase leads to population decline, Under Development 292: Inhibition of tyrosinase leads to decreased population in fish, Under Development 289: Inhibition of 5α-reductase leading to impaired fecundity in female fish, Under Development 318: Glucocorticoid Receptor activation leading to hepatic steatosis 264: Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death, Under Development 265: Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium, Under Development 266: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity, Under Development 267: Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion, Under Development 268: Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling, Under Development 348: Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory , Under Development 349: Inhibition of 11β-hydroxylase leading to decresed population trajectory , Under Development 43: Disruption of VEGFR Signaling Leading to Developmental Defects, WPHA/WNT Endorsed 41: Sustained AhR Activation leading to Rodent Liver Tumours, Under Review 323: PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone 563: Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis 577: AhR activation leading to endometriosis 39: Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response, Under Development 581: Glucocorticoid receptor (GR) activation during development leads to cognitive function (COG) decrease	19
Cinzia La Rocca	Istituto Superiore di Sanità	toggle AOPs 51: PPARα activation leading to impaired fertility in adult male rodents , Under Development 379: Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation, Under Development 392: Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation, Under Development 412: Endothelial cell dysfunction leading to thromboinflammation, Under Development 430: Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation, Under Development 173: Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis, WPHA/WNT Endorsed 302: Lung surfactant function inhibition leading to decreased lung function, Under Development 382: Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis, Under Development 320: Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality, Under Development 374: Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis, Under Development 394: SARS-CoV-2 infection of olfactory epithelium leading to impaired olfactory function (short-term anosmia), Under Development 395: Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on pericytes leads to disseminated intravascular coagulation resulting in cerebrovascular disease (stroke), Under Development 422: Binding of SARS-CoV-2 to ACE2 in enterocytes leads to intestinal barrier disruption, Under Development 428: Binding of S-protein to ACE2 in enterocytes induces ACE2 dysregulation leading to gut dysbiosis , Under Development 319: Binding to ACE2 leading to lung fibrosis, Under Development 130: Phospholipase A2 (LPLA2) inhibitors leading to hepatotoxicity, Under Development	16
Rex FitzGerald		toggle AOPs 316: Trypsin inhibition leading to pancreatic acinar cell tumors, Under Development 295: Early-life stromal estrogen receptor activation by endocrine disrupting chemicals in the mammary gland leading to enhanced cancer risk, Under Development 148: EGFR Activation Leading to Decreased Lung Function, Under Development 411: Oxidative stress Leading to Decreased Lung Function 440: Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia, Under Development 474: Succinate dehydrogenase inactivation leads to cancer by promoting EMT, Under Development 475: Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons, Under Development 43: Disruption of VEGFR Signaling Leading to Developmental Defects, WPHA/WNT Endorsed 546: Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms	9
Judy Choi	German Federal Institute for Risk Assessment	toggle AOPs 295: Early-life stromal estrogen receptor activation by endocrine disrupting chemicals in the mammary gland leading to enhanced cancer risk, Under Development 305: 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring, Under Review 306: Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring, Under Review 307: Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring, Under Review 344: Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring, Under Development 345: Androgen receptor (AR) antagonism leading to decreased fertility in females, Under Development 460: Antagonism of Smoothened receptor leading to orofacial clefting, Under Review 502: Decrease, cholesterol synthesis leads to orofacial clefting, Under Development	8
Sabina Halappanavar	Health Canada	toggle AOPs 314: Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE), Under Development 303: Frustrated phagocytosis-induced lung cancer, Under Development 302: Lung surfactant function inhibition leading to decreased lung function, Under Development 347: Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis 237: Substance interaction with lung resident cell membrane components leading to atherosclerosis, Under Development	5
Brigitte Landesmann	JRC European Commission	toggle AOPs 319: Binding to ACE2 leading to lung fibrosis, Under Development 320: Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality, Under Development 479: Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress, Under Development 480: Mitochondrial complexes inhibition leading to heart failure via decreased ATP production, Under Development	4
Tanja Burgdorf	German Federal Institute for Risk Assessment	toggle AOPs 293: Increased DNA damage leading to increased risk of breast cancer, Under Development 294: Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer, Under Development 439: Activation of the AhR leading to metastatic breast cancer , Under Review 494: AhR activation leading to liver fibrosis	4
You Song	Norwegian Institute for Water Research (NIVA)	toggle AOPs 398: Decreased ALDH1A (RALDH) activity leading to decreased fertility via disrupted meiotic initiation of fetal oogonia , Under Development 437: Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity, Under Development 298: Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer, Under Review 604: Binding of Alpha 1-Adrenergics to Antagonists Leading to Depression	4
Edward Perkins		toggle AOPs 298: Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer, Under Review 316: Trypsin inhibition leading to pancreatic acinar cell tumors, Under Development	2
Jason M. O'Brien		toggle AOPs 39: Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response, Under Development 296: Oxidative DNA damage leading to chromosomal aberrations and mutations, WPHA/WNT Endorsed	2
Julija Filipovska		toggle AOPs 313: Stimulation of TLR7/8 in dendric cells leading to Psoriatic skin disease, Under Development	1
Olga Tcheremenskaia	Istituto Superiore di Sanità	toggle AOPs 151: AhR activation leading to preeclampsia, Under Development	1
Knut Erik Tollefsen	Norwegian Institute for Water Research (NIVA), Gaustadalléen 21, N-0349 OSLO	toggle AOPs 413: Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure	1
Stefan Scholz		toggle AOPs 433: hERG channel blockade leading to sudden cardiac death	1
Barbara Viviani	Department of Biomolecular and Pharmacological Sciences, Università degli Studi di Milano	toggle AOPs 442: Binding to voltage gate sodium channels during development leads to cognitive impairment, WPHA/WNT Endorsed	1
Alexander Cole	U.S. Environmental Protection Agency	toggle AOPs 14: Glucocorticoid Receptor Activation Leading to Increased Disease Susceptibility	1